Table S1. RNA-Expression of Spalax. RNA expression divided between the different samples. Table S2. 68 differentially expressed genes in carcinogen resistant Spalax. Table S3. miRNA analysis in Spalax candidate genes. Differential expression analysis of miRNAs in Spalax samples. Table S4. miRNA analysis in Spalax ECM genes. Differential expression analysis of miRNAs in Spalax samples of ECM related genes. Table S5. Expression values of Fanconi Anemia genes. Differential expression analysis for Fanconi Anemia genes in Spalax. Table S6. Differential expression analysis of Spalax UIS vs tumor. A |log2FC| ≥ 2 is a threshold for highly differentially expressed genes. We filtered the genes that belong to these categories: cell cycle, citrate cycl...
The genes targeted by downregulated miRNAs. Table S2. The genes targeted by upregulated miRNAs. (XLS...
Figure S3. Pathway enrichment by RNA-Seq. Dot plots showing the enrichment results of KEGG pathway a...
Clinical characteristics of patients with colorectal cancer in this study. Table S2. Tumor response ...
Abstract Background Spalax, the blind mole rat, developed an extraordinary cancer resistance during ...
Genes upregulated during liver metastasis; cancer and organ-specific changes. DESeq2 was used to ide...
Table S1. Cell cultivation conditions. Table S2. Primers used in the present study. Table S3. Primar...
Genes upregulated during lung metastasis; cancer and organ-specific changes. DESeq2 was used to iden...
Table S1. Detailed information of cohort 1 and 2 is listed. Table S2. Primers and RNA sequences used...
Detailed information of tumoral characteristics of patients and the information of metastasis. *The ...
Table S1. Provides a complete list of the genes identified by GSEA analysis contributing to the upre...
Table S1. miRNAs differentialy expressed in NPC versus control. Table S2. The top 20 most significan...
contains Tables S1-S9. Table S1. Results of the primary yeast screen with RAS alleles RAS1 and RAS2 ...
Table S1. Sequence of miR-214 mimic and negative control. Table S2. Primers used in Real time-PCR te...
Table S1. A general linear model for average methylation change attributed to genomic annotations of...
Supplementary information. Table S1 Primers and TaqMan assays used in this study; Table S2 microRNAs...
The genes targeted by downregulated miRNAs. Table S2. The genes targeted by upregulated miRNAs. (XLS...
Figure S3. Pathway enrichment by RNA-Seq. Dot plots showing the enrichment results of KEGG pathway a...
Clinical characteristics of patients with colorectal cancer in this study. Table S2. Tumor response ...
Abstract Background Spalax, the blind mole rat, developed an extraordinary cancer resistance during ...
Genes upregulated during liver metastasis; cancer and organ-specific changes. DESeq2 was used to ide...
Table S1. Cell cultivation conditions. Table S2. Primers used in the present study. Table S3. Primar...
Genes upregulated during lung metastasis; cancer and organ-specific changes. DESeq2 was used to iden...
Table S1. Detailed information of cohort 1 and 2 is listed. Table S2. Primers and RNA sequences used...
Detailed information of tumoral characteristics of patients and the information of metastasis. *The ...
Table S1. Provides a complete list of the genes identified by GSEA analysis contributing to the upre...
Table S1. miRNAs differentialy expressed in NPC versus control. Table S2. The top 20 most significan...
contains Tables S1-S9. Table S1. Results of the primary yeast screen with RAS alleles RAS1 and RAS2 ...
Table S1. Sequence of miR-214 mimic and negative control. Table S2. Primers used in Real time-PCR te...
Table S1. A general linear model for average methylation change attributed to genomic annotations of...
Supplementary information. Table S1 Primers and TaqMan assays used in this study; Table S2 microRNAs...
The genes targeted by downregulated miRNAs. Table S2. The genes targeted by upregulated miRNAs. (XLS...
Figure S3. Pathway enrichment by RNA-Seq. Dot plots showing the enrichment results of KEGG pathway a...
Clinical characteristics of patients with colorectal cancer in this study. Table S2. Tumor response ...